MI-CP151 was a phase 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre examine To judge several intravenous doses of sifalimumab, in adult people with dermatomyositis or polymyositis (NCT00533091). Major trial objectives have been To judge the security and tolerability of sifalimumab in dermatomyositis or polymyositis people, whilst on the list of https://baltasarj122nyk5.newsbloger.com/profile